Diabetes

Cardiovascular Event Risk Not Increased With Liraglutide

Cardiovascular Event Risk Not Increased With Liraglutide

Liraglutide treatment for weight management is not associated with increased risk of cardiovascular event.

Type 2 Diabetes Risks in Heart Failure Can Be Stratified by Glycemic Control

Type 2 Diabetes Risks in Heart Failure Can Be Stratified by Glycemic Control

For patients with heart failure, the risks conferred by type 2 diabetes can be stratified by glycemic control and drug treatments

LV Diastolic Function Improved in Diabetes With Pioglitazone

LV Diastolic Function Improved in Diabetes With Pioglitazone

Pioglitazone improves whole-body and myocardial insulin sensitivity, left ventricular diastolic function, and systolic function in patients with type 2 diabetes.

Insulin Resistance, Cardiometabolic Risk Increased in Obese Children

Insulin Resistance, Cardiometabolic Risk Increased in Obese Children

Cardiometabolic risk and homeostatic model assessment of insulin resistance increase with increased body mass index.

Insulin Dose Not Tied to Cardiovascular Outcomes

Insulin Dose Not Tied to Cardiovascular Outcomes

Cardiovascular outcomes in patients with diabetes are not explained by insulin resistance.

Prognostic Significance of Gender in Atrial Fibrillation and Diabetes

Prognostic Significance of Gender in Atrial Fibrillation and Diabetes

By

Women with atrial fibrillation and diabetes have higher rates for mortality and cardiovascular disease compared to men.

Cardiovascular Risk in Type 2 Diabetes Not Increased With Exenatide

Cardiovascular Risk in Type 2 Diabetes Not Increased With Exenatide

The risk of major cardiovascular events is similar for those receiving exenatide or placebo for patients with type 2 diabetes.

ADA Issues Position Statement on Hypertension Management in Diabetes

ADA Issues Position Statement on Hypertension Management in Diabetes

By

The American Diabetes Association has updated its recommendations on the assessment and treatment of hypertension in individuals with diabetes.

SGLT2 vs DPP4 Medications Associated with Lower Heart Failure Hospitalizations in Type 2 Diabetes

SGLT2 vs DPP4 Medications Associated with Lower Heart Failure Hospitalizations in Type 2 Diabetes

By

Patients with type 2 diabetes who received sodium-glucose co-transporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors had a lower risk for heart failure hospitalizations.

Atrial Fibrillation Risk Increased With Type 1 Diabetes, Poor Renal Function

Atrial Fibrillation Risk Increased With Type 1 Diabetes, Poor Renal Function

By

Patients with type 1 diabetes have an increased risk for atrial fibrillation.

Liraglutide Receives FDA Approval For MACE Reduction in Type 2 Diabetes

Liraglutide Receives FDA Approval For MACE Reduction in Type 2 Diabetes

By

Liraglutide has received approval by the US Food and Drug Administration for a new indication to reduce the risk of MACE in type 2 diabetes patients.

Type 2 Diabetes Medication Adherence Not Reported in Studies

Type 2 Diabetes Medication Adherence Not Reported in Studies

Studies often fail to include information on outcomes by medication adherence in type 2 diabetes.

Independent Predictors of Silent Coronary Artery Disease in Asymptomatic Diabetes

Independent Predictors of Silent Coronary Artery Disease in Asymptomatic Diabetes

By

Smoking, duration of diabetes, and male sex were among several independent predictors of silent coronary artery disease in patients with asymptomatic diabetes.

Benefits of Intensive SBP Treatment Extend to Patients WIth Prediabetes

Benefits of Intensive SBP Treatment Extend to Patients WIth Prediabetes

The beneficial effects of intensive systolic blood pressure treatment are similar among those with prediabetes and fasting normoglycemia.

Insulin Initiation Associated With Weight Gain, Acitvity Decreases in T2D

Insulin Initiation Associated With Weight Gain, Acitvity Decreases in T2D

By

Initiation of insulin therapy in patients with type 2 diabetes was associated to inactivity and weight gain.

Hypertension, Diabetes in Midlife Increase Risk of Dementia

Hypertension, Diabetes in Midlife Increase Risk of Dementia

Risk factors for dementia include midlife vascular risk factors such as hypertension, diabetes and smoking.

Multiple Cardiometabolic Comorbidities Prevalent in Psoriasis

Multiple Cardiometabolic Comorbidities Prevalent in Psoriasis

By

Patients with psoriasis have high rates of cardiometabolic comorbidities.

Increases in NT-proBNP and hsTnI Delayed in Type 2 Diabetes With Canagliflozin

Increases in NT-proBNP and hsTnI Delayed in Type 2 Diabetes With Canagliflozin

Canagliflozin delayed the rise in several cardiac biomarkers for over 2 years in older type 2 diabetes patients patients.

FDA Approves Pitavastatin as Adjunctive Therapy for Hyperlipidemia or Mixed Dyslipidemia

FDA Approves Pitavastatin as Adjunctive Therapy for Hyperlipidemia or Mixed Dyslipidemia

By

The FDA has approved Zypitamag for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia.

Left Ventricular Function in Type 1 Diabetes Improves With Exercise

Left Ventricular Function in Type 1 Diabetes Improves With Exercise

Adolescents with type 1 diabetes may benefit from a 20 week exercise training intervention that's associated with improved aerobic capacity and stroke volume.

Diabetes Increases Hospital Readmissions Rates

Diabetes Increases Hospital Readmissions Rates

By

Patients with diabetes had a higher rate of readmission to hospitals compared with patients without diabetes.

Two-Hour Postload Glucose Predicts CV Events Better Than Fasting Glucose, HbA1C

Two-Hour Postload Glucose Predicts CV Events Better Than Fasting Glucose, HbA1C

By

Two-hour postload glucose (2h-PG) may be a better predictor of cardiovascular events in patients with coronary artery disease.

Heart Failure in Type 2 Diabetes: Improving the Risk Model

Heart Failure in Type 2 Diabetes: Improving the Risk Model

By

N-terminal pro-B-type natriuretic peptide showed the strongest association with heart failure in patients with type 2 diabetes.

Cardiovascular Risk in Type 2 Diabetes Reduced With Electronic Messaging

Cardiovascular Risk in Type 2 Diabetes Reduced With Electronic Messaging

An electronic messaging intervention is effective for reducing cardiovascular risk for patients with type 2 diabetes.

FDA Tentatively Approves Follow-On Biologic Basal Insulin Glargine

FDA Tentatively Approves Follow-On Biologic Basal Insulin Glargine

Tentative FDA approval has been granted to Merck's follow-on biologic basal insulin injection, Lusduna Nexvue.

CVD Risk in Diabetes Predicted by Visceral to Subcutaneous Fat Area Ratio

CVD Risk in Diabetes Predicted by Visceral to Subcutaneous Fat Area Ratio

In patients with increasing visceral to subcutaneous fat area ratio quartiles, there were more first or recurring cardiovascular disease.

Major Cardiovascular Events in Diabetes Predicted Coronary CT Angiography

Major Cardiovascular Events in Diabetes Predicted Coronary CT Angiography

CCTA-detected obstructive coronary artery disease (CAD) improves prediction of MACE in patients with type 2 diabetes.

Glycemic Control Improves With Hepatitis C Treatment

Glycemic Control Improves With Hepatitis C Treatment

Direct-acting antiviral treatment for hepatitis C virus is linked to improved glycemic control in patients with type 2 diabetes.

Chronic Inflammatory Disorders Increase Cardiometabolic and Mortality Risks

Chronic Inflammatory Disorders Increase Cardiometabolic and Mortality Risks

By

The degree of risk for cardiometabolic events and all-cause mortality increased with nonsteroidal anti-inflammatory drugs and corticosteroid drugs.

Blood Pressure Reductions With SGLT2 Inhibitors in Type 2 Diabetes

Blood Pressure Reductions With SGLT2 Inhibitors in Type 2 Diabetes

By

Sodium-glucose cotransporter 2 inhibitors produce an off-target effect on blood pressure in type 2 diabetes patients.

Sign Up for Free e-Newsletters